French hip resurfacing registry: A study of 1650 cases

Conversion of hip resurfacing to total hip arthroplasty: is the outcome closer to primary or revision total hip arthroplasty?

BACKGROUND

Along with the advent of newer bearings, hip resurfacing (HR) is gaining renewed interest as a bone sparing alternative to conventional total hip arthroplasty (THA) in young patients. However, the outcome of conversion of failed HR to THA (HRc) remains sparsely described. This study aimed to compare the outcomes and complication rates of HRc to those of primary (pTHA) and revision THA (rTHA) to find out to which group HRc is most comparable.

HYPOTHESIS

The study hypothesis was that the outcomes and complications rates of HRc were closer to those of pTHA than rTHA.

MATERIALS AND METHODS

Between 2001 and 2011, a continuous series of 207 HR were prospectively included in our institutional registry and retrospectively analyzed. Out of them, 17 HR (8%) were converted to THA. Propensity scores were used to match patients in the HRc group to the pTHA and the rTHA groups using a greedy 1:3 matching procedure (51 pTHA and 51 rTHA). Clinical and radiographic outcomes, perioperative data and complications were analyzed and compared between the three groups.

RESULTS

No significant difference between HRc and pTHA was observed in terms of clinical and functional outcomes, duration of surgery, acetabular component diameter and length of hospital stay (p = 0.13 to 0.94). Perioperative blood loss was significantly lower for pTHA than for HRc (p = 0.01). HRc demonstrated significantly higher HHS and HOOS scores than for rTHA at one year (p = 0.03 and p < 0.01, respectively). Duration of surgery was significantly lower in HRc compared to rTHA (p = 0.02) while length of hospital stay was similar (p = 0.84). Complication rate was significantly higher in the rTHA group, compared to HRc and pTHA groups (37.3 vs. 29.4 vs. 11.8%, p = 0.01).

CONCLUSION

This study demonstrated that the clinical and functional outcomes of HRc were closer to those of pTHA than those of rTHA, though complication rate was higher than for pTHA.

LEVEL OF EVIDENCE

III; Retrospective comparative study.

What role for short stems in 2023?

Current trends in total hip replacement aim at soft tissue and bone stock conservation. At the same time, mean patient age has been decreasing from decade to decade, raising the issue of iterative revision. Short stems seek to resolve the problem on the femoral side. Hopefully, revision of a short stem will be easier and bone stock depletion will be less than with a standard stem. Short stems also seem to have other advantages: automatically personalized biomechanical reconstruction, easier minimally invasive strategies, very low rate of hip pain, more harmonious distribution of bone stress, etc. Despite these advantages, however, use of short stems since their introduction in the late 1980s has varied from country to country, and is not widespread in France. The present study addressed several questions concerning these implants. Firstly, what is a "short" stem? Then, what are the indications and contraindications? Shortened standard stems do not come under the concept of short stem and will not be dealt with here. Furthermore, the learning curve and specificities of short stems need to be acquired. Implantation technique differs greatly from standard stems, and short stem implantation requires particular rigor. Results also need to be assessed, and especially the rate of complications as compared to standard stems. And lastly, it needs to be determined whether the advantages are real or only theoretical: this will determine their usefulness and role in the armamentarium, in which short stems are a new paradigm. LEVEL OF EVIDENCE: Expert opinion.

Global mapping of institutional and hospital-based (Level II-IV) arthroplasty registries: a scoping review

PURPOSE

Four joint arthroplasty registries (JARs) levels exist based on the recorded data type. Level I JARs are national registries that record primary data. Hospital or institutional JARs (Level II-IV) document further data (patient-reported outcomes, demographic, radiographic). A worldwide list of Level II-IV JARs must be created to effectively assess and categorize these data.

METHODS

Our study is a systematic scoping review that followed the PRISMA guidelines and included 648 studies. Based on their publications, the study aimed to map the existing Level II-IV JARs worldwide. The secondary aim was to record their lifetime, publications' number and frequency and recognise differences with national JARs.

RESULTS

One hundred five Level II-IV JARs were identified. Forty-eight hospital-based, 45 institutional, and 12 regional JARs. Fifty JARs were found in America, 39 in Europe, nine in Asia, six in Oceania and one in Africa. They have published 485 cohorts, 91 case-series, 49 case-control, nine cross-sectional studies, eight registry protocols and six randomized trials. Most cohort studies were retrospective. Twenty-three per cent of papers studied patient-reported outcomes, 21.45% surgical complications, 13.73% postoperative clinical and 5.25% radiographic outcomes, and 11.88% were survival analyses. Forty-four JARs have published only one paper. Level I JARs primarily publish implant revision risk annual reports, while Level IV JARs collect comprehensive data to conduct retrospective cohort studies.

CONCLUSIONS

This is the first study mapping all Level II-IV JARs worldwide. Most JARs are found in Europe and America, reporting on retrospective cohorts, but only a few report on studies systematically.

Resurfacing Hip Arthroplasty Is a Safe and Effective Alternative to Total Hip Arthroplasty in Young Patients: A Systematic Review and Meta-Analysis

This systematic review and meta-analysis of randomized controlled trials (RCTs) aimed at comparing resurfacing hip arthroplasty (RHA) and total hip arthroplasty (THA) in terms of rate of complications, revisions, functional outcomes, blood loss, operative time and metal ions levels. The search was conducted on three databases (PubMed, Cochrane and Web of Science) updated until 13 October 2022. The inclusion criteria were RCTs) written in the English language, with no time limitation, comparing RHA and THA. Among the retrieved 4748 articles, 18 RCTs were eligible for a total of 776 patients (mean age 53.1 ± 5.0). A meta-analysis was performed. RHA reported significantly lower blood loss compared to THA (p < 0.001) but with longer operative time (p < 0.001). No statistically significant difference was found between RHA and THA in terms of complications (12.08% and 16.24%, respectively) and revisions (6.32% and 6.14%, respectively). Both RHA and THA provide excellent clinical results in a population of young and active patients. Functional outcomes were not significantly different between the groups. Moreover, no significant difference in metal ion levels was found. These findings provide evidence concerning the safety and clinical effectiveness of RHA. Because of its bone-preserving properties, the lack of drawbacks and good outcomes, RHA appears to be a valid alternative to THA in young and active patients.

Consensus statement on data to be entered in the ACL tear registry: SFA-DataLake

INTRODUCTION

Anterior cruciate ligament (ACL) reconstruction is a frequent procedure, with room for improvement by rehabilitation measures and associated peripheral and meniscal surgeries that are currently under assessment, requiring follow-up. Outside France, there have been ACL registries for 20 years now. The French Arthroscopy Society (SFA) decided to set up an ACL tear registry within its SFA DataLake registry platform.

MATERIAL AND METHOD

This article presents the methodology underlying the ACL Tear Registry: i.e., identification, definition and coding of essential and relevant data. A test phase comprised an initial assessment to improve data quality and overall coherence, to optimize data-entry time for patients and practitioners, who are the guarantors of the registry's use and efficacy.

RESULTS

The SFA DataLake ACL Tear Registry was made available to SFA members in December 2021. It aims to enable a review of practices for surgeons, early detection of failure of procedures and implants, with rates of failure and abnormal complications, and identification of prognostic factors for outcome, especially regarding original items that do not figure in previous registries.

CONCLUSION

SFA DataLake strikes a balance between "indispensable" and "original" items. The choice of contents and data quality is founded on a robust methodology with overall coherence, enabling analysis of large cohorts and comparisons with the literature and other registries. However, it remains to assess rates of data entry and item relevance as the Registry progresses.

LEVEL OF EVIDENCE

IV.

Debridement, antibiotics and implant retention for prosthetic joint infection: comparison of outcomes between total hip arthroplasty and hip resurfacing

INTRODUCTION

The management of prosthetic joint infection (PJI) has been widely studied in the context of total hip arthroplasty (THA). However, the outcomes of debridement, antibiotics and implant retention (DAIR) for PJI have never been compared between hip resurfacing arthroplasty (HRA) and THA. This led us to carry out a retrospective case-control study comparing the surgical treatment of post-operative infections between HRA and THA to determine the infection remission rate and the medium-term functional outcomes.

METHODS

This single-centre case-control study analysed 3056 HRA cases of which 13 patients had a PJI treated by DAIR. These patients were age-matched with 15 infected THA hips treated by DAIR and modular component exchange (controls). Their survival (no recurrence of the infection) was compared and factors that could affect the success of the DAIR were explored: sex, body mass index, age at surgery, presence of haematoma, type of bacteria present and antibiotic therapy.

RESULTS

At a mean follow-up of five years (2-7), the infection control rate was significantly higher in the HRA group (100% [13/13]) than in the THA group (67% [10/15]) (p = 0.044). More patients in the THA group had undergone early DAIR (< 30 days) (73% [11/15]) than in the HRA group (54% [7/13]). There was no significant difference between the two groups in the ASA score, presence of comorbidities, body mass index and duration of the initial arthroplasty procedure. At the review, the Oxford-12 score of 17/60 (12-28) was better in the HRA group than the score of 25/60 (12-40) in the THA group (p = 0.004).

CONCLUSION

DAIR, no matter the time frame, is a viable therapeutic option for infection control after HRA.